BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 26582061)

  • 41. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome.
    Niessen RC; Hofstra RM; Westers H; Ligtenberg MJ; Kooi K; Jager PO; de Groote ML; Dijkhuizen T; Olderode-Berends MJ; Hollema H; Kleibeuker JH; Sijmons RH
    Genes Chromosomes Cancer; 2009 Aug; 48(8):737-44. PubMed ID: 19455606
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk of gynecologic cancers in Danish hereditary non-polyposis colorectal cancer families.
    Boilesen AE; Bisgaard ML; Bernstein I
    Acta Obstet Gynecol Scand; 2008; 87(11):1129-35. PubMed ID: 18972272
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Spectrum of MLH1 and MSH2 mutations in Chilean families with suspected Lynch syndrome.
    Alvarez K; Hurtado C; Hevia MA; Wielandt AM; de la Fuente M; Church J; Carvallo P; López-Köstner F
    Dis Colon Rectum; 2010 Apr; 53(4):450-9. PubMed ID: 20305446
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluating the performance of clinical criteria for predicting mismatch repair gene mutations in Lynch syndrome: a comprehensive analysis of 3,671 families.
    Steinke V; Holzapfel S; Loeffler M; Holinski-Feder E; Morak M; Schackert HK; Görgens H; Pox C; Royer-Pokora B; von Knebel-Doeberitz M; Büttner R; Propping P; Engel C;
    Int J Cancer; 2014 Jul; 135(1):69-77. PubMed ID: 24493211
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Validation microsatellite path score in a population-based cohort of patients with colorectal cancer.
    Bessa X; Alenda C; Paya A; Álvarez C; Iglesias M; Seoane A; Dedeu JM; Abulí A; Ilzarbe L; Navarro G; Pellise M; Balaguer F; Castellvi-Bel S; Llor X; Castells A; Jover R; Andreu M
    J Clin Oncol; 2011 Sep; 29(25):3374-80. PubMed ID: 21788563
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Constitutional Mismatch Repair Deficiency in Israel: High Proportion of Founder Mutations in MMR Genes and Consanguinity.
    Baris HN; Barnes-Kedar I; Toledano H; Halpern M; Hershkovitz D; Lossos A; Lerer I; Peretz T; Kariv R; Cohen S; Half EE; Magal N; Drasinover V; Wimmer K; Goldberg Y; Bercovich D; Levi Z
    Pediatr Blood Cancer; 2016 Mar; 63(3):418-27. PubMed ID: 26544533
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Frequent mismatch-repair defects link prostate cancer to Lynch syndrome.
    Dominguez-Valentin M; Joost P; Therkildsen C; Jonsson M; Rambech E; Nilbert M
    BMC Urol; 2016 Mar; 16():15. PubMed ID: 27013479
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evidence of constitutional MLH1 epimutation associated to transgenerational inheritance of cancer susceptibility.
    Crépin M; Dieu MC; Lejeune S; Escande F; Boidin D; Porchet N; Morin G; Manouvrier S; Mathieu M; Buisine MP
    Hum Mutat; 2012 Jan; 33(1):180-8. PubMed ID: 21953887
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.
    Skeldon SC; Semotiuk K; Aronson M; Holter S; Gallinger S; Pollett A; Kuk C; van Rhijn B; Bostrom P; Cohen Z; Fleshner NE; Jewett MA; Hanna S; Shariat SF; Van Der Kwast TH; Evans A; Catto J; Bapat B; Zlotta AR
    Eur Urol; 2013 Feb; 63(2):379-85. PubMed ID: 22883484
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nationwide study of clinical and molecular features of hereditary non-polyposis colorectal cancer (HNPCC) in Latvia.
    Irmejs A; Borosenko V; Melbarde-Gorkusa I; Gardovskis A; Bitina M; Kurzawski G; Suchy J; Gorski B; Gardovskis J
    Anticancer Res; 2007; 27(1B):653-8. PubMed ID: 17348456
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analysis of telomere dynamics in peripheral blood cells from patients with Lynch syndrome.
    Bozzao C; Lastella P; Ponz de Leon M; Pedroni M; Di Gregorio C; D'Ovidio FD; Resta N; Prete F; Guanti G; Stella A
    Cancer; 2011 Sep; 117(18):4325-35. PubMed ID: 21387278
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Simplified identification of Lynch syndrome: a prospective, multicenter study.
    Bonnet D; Selves J; Toulas C; Danjoux M; Duffas JP; Portier G; Kirzin S; Ghouti L; Carrère N; Suc B; Alric L; Barange K; Buscail L; Chaubard T; Imani K; Guimbaud R
    Dig Liver Dis; 2012 Jun; 44(6):515-22. PubMed ID: 22480969
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Short-term risk of colorectal cancer in individuals with lynch syndrome: a meta-analysis.
    Jenkins MA; Dowty JG; Ait Ouakrim D; Mathews JD; Hopper JL; Drouet Y; Lasset C; Bonadona V; Win AK
    J Clin Oncol; 2015 Feb; 33(4):326-31. PubMed ID: 25534380
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.
    Lagerstedt-Robinson K; Rohlin A; Aravidis C; Melin B; Nordling M; Stenmark-Askmalm M; Lindblom A; Nilbert M
    Oncol Rep; 2016 Nov; 36(5):2823-2835. PubMed ID: 27601186
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.
    Schiemann U; Müller-Koch Y; Gross M; Daum J; Lohse P; Baretton G; Muders M; Mussack T; Kopp R; Holinski-Feder E
    Digestion; 2004; 69(3):166-76. PubMed ID: 15118395
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients.
    Hampel H; Frankel W; Panescu J; Lockman J; Sotamaa K; Fix D; Comeras I; La Jeunesse J; Nakagawa H; Westman JA; Prior TW; Clendenning M; Penzone P; Lombardi J; Dunn P; Cohn DE; Copeland L; Eaton L; Fowler J; Lewandowski G; Vaccarello L; Bell J; Reid G; de la Chapelle A
    Cancer Res; 2006 Aug; 66(15):7810-7. PubMed ID: 16885385
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations.
    Joost P; Therkildsen C; Dominguez-Valentin M; Jönsson M; Nilbert M
    Urology; 2015 Dec; 86(6):1212-7. PubMed ID: 26385421
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The mutational spectrum of Lynch syndrome in cyprus.
    Loizidou MA; Neophytou I; Papamichael D; Kountourakis P; Vassiliou V; Marcou Y; Kakouri E; Ioannidis G; Philippou C; Spanou E; Tanteles GA; Anastasiadou V; Hadjisavvas A; Kyriacou K
    PLoS One; 2014; 9(8):e105501. PubMed ID: 25133505
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Performance of PREMM(1,2,6), MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases.
    Mercado RC; Hampel H; Kastrinos F; Steyerberg E; Balmana J; Stoffel E; Cohn DE; Backes FJ; Hopper JL; Jenkins MA; Lindor NM; Casey G; Haile R; Madhavan S; de la Chapelle A; Syngal S;
    Genet Med; 2012 Jul; 14(7):670-80. PubMed ID: 22402756
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds.
    Grindedal EM; Renkonen-Sinisalo L; Vasen H; Evans G; Sala P; Blanco I; Gronwald J; Apold J; Eccles DM; Sánchez AA; Sampson J; Järvinen HJ; Bertario L; Crawford GC; Stormorken AT; Maehle L; Moller P
    J Med Genet; 2010 Feb; 47(2):99-102. PubMed ID: 19635727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.